Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy.
Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy.
复制标题
非编码 RNA 多态性（rs2910164 和 rs1333049）与铂类化疗下肺癌的预后相关
DOI：
10.3389/fphar.2021.709528
复制
发表时间：
2021
影响因子：
5.6
通讯作者：
Liu ZQ
中科院分区：
文献类型：
--
作者：
Chen YX;Chen J;Yin JY;Zhou HH;He BM;Liu ZQ
目的：肺癌是全球癌症死亡的首要原因。以铂类为基础的化疗是一线化疗的基础。然而，以铂类为基础的化疗治疗肺癌的预后仍然是一个挑战。非编码RNA的单核苷酸多态性有可能成为生物标志物，但其有效性尚未得到全面评估。在本研究中，我们探讨了非编码RNA多态性与接受铂类化疗的肺癌患者预后之间的关联。
材料与方法：对446例接受铂类化疗的肺癌患者，采用基质辅助激光解吸电离飞行时间质谱法对微小RNA和长链非编码RNA的22个单核苷酸多态性进行基因分型。采用Cox回归分析、Kaplan - Meier法和对数秩检验来评估多态性与总生存期和无进展生存期的关联。
结果：在加性和显性模型中，ANRIL rs1333049（G＞C）的基因多态性与无进展生存期显著相关。加性模型：CC组与GC组与GG组相比[风险比（HR）= 0.84，p = 0.021，95%置信区间（CI）为（0.73 - 0.97）]；隐性模型：CC组与GG + GC组相比[HR = 0.77，p = 0.026，95%CI为（0.61 - 0.97）]。在显性模型中，与CC基因型患者相比，miR - 146A rs2910164中CG或GG基因型患者的死亡风险更低[HR = 0.81，p = 0.036，95%CI为（0.66 - 0.99）]，进展风险也更低[HR = 0.81，p = 0.040，95%CI为（0.67 - 0.99）]。
结论：我们的研究表明，ANRIL rs1333049（G＞C）和miR - 146A rs2910164（C＞G）有作为生物标志物的潜力，可用于支持对接受铂类化疗的肺癌患者更好预后的预测。
Purpose: Lung cancer is the largest cause of cancer deaths in the world. Platinum-based chemotherapy is a foundation of first-line chemotherapy. However, the prognosis of lung cancer treated with platinum-based chemotherapy is still a challenge. Single nucleotide polymorphism of non-coding RNA has the potential to be a biomarker, but its effectiveness has yet to be comprehensively assessed. In this study, we explored the association between polymorphisms of non-coding RNA and prognosis of lung cancer patients receiving platinum-based chemotherapy. Materials and Methods: For 446 lung cancer patients receiving platinum-based chemotherapy, 22 single nucleotide polymorphisms of microRNA and long noncoding RNA were genotyped by MALDI-TOF mass spectrometry. Cox regression analysis, Kaplan-Meier method, and long-rank test have been performed to assess the association of overall and progression-free survival with polymorphisms. Results: In the additive and dominant models, genetic polymorphism of ANRIL rs1333049 (G > C) was significantly associated with progression-free survival. Additive model: CC vs GC vs GG [HR = 0.84, p = 0.021, 95% CI (0.73–0.97)]; Recessive model: CC vs GG + GC [HR = 0.77, p = 0.026, 95% CI (0.61–0.97)]. In the dominant model, compared with the CC genotype patients, lower risk of death [HR = 0.81, p = 0.036, 95% CI (0.66–0.99)] and lower risk of progression [HR = 0.81, p = 0.040, 95% CI (0.67–0.99)] have been observed on the patients with CG or GG genotype in miR-146A rs2910164. Conclusion: Our research demonstrated the potential of using ANRIL rs1333049 (G > C) and miR-146A rs2910164 (C > G) as biomarkers to support the prediction of a better prognosis for lung cancer patients receiving platinum-based chemotherapy.
登录
查看更多内容
影响因子：
--
作者：
Gong, Wei-Jing;Yin, Ji-Ye;Liu, Zhao-Qian
通讯作者：
Liu, Zhao-Qian
影响因子：
3.7
作者：
An J;Liu J;Liu L;Liu Y;Pan Y;Huang M;Qi F;Wen J;Xie K;Ma H;Shen H;Hu Z
通讯作者：
Hu Z
年龄相关的常见 miRNA 多态性与接受铂类化疗的肺癌患者的严重毒性相关
DOI：
10.1111/1440-1681.12704
发表时间：
2017-12-01
影响因子：
2.9
作者：
Fang, Chao;Li, Xiang-Ping;Liu, Zhao-Qian
通讯作者：
Liu, Zhao-Qian
长非编码 RNA ANRIL 通过沉默 KLF2 和 P21 表达促进非小细胞肺癌细胞增殖并抑制细胞凋亡。
影响因子：
5.7
作者：
Nie, Feng-qi;Sun, Ming;Shu, Yong-qian
通讯作者：
Shu, Yong-qian
DOI：
10.1073/pnas.0802682105
发表时间：
2008-05-20
影响因子：
11.1
作者：
Jazdzewski, Krystian;Murray, Elizabeth L.;de la Chapelle, Albert
通讯作者：
de la Chapelle, Albert